John Miura

Dr. John Miura

Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
RSRichard J. Straker
Richard J. Straker
MCMichael J. Carr
Michael J. Carr
ASAndrew J. Sinnamon
Andrew J. Sinnamon
ASAdrienne B. Shannon
Adrienne B. Shannon
JSJames Sun
James Sun
John MiuraJohn Miura
John Miura

26 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OBOmar Bushara
Omar Bushara
JTJerica Tidwell
Jerica Tidwell
JWJames R. Wester
James R. Wester
John MiuraJohn Miura
John Miura
The advent of effective immunotherapy and targeted therapy has significantly improved outcomes in advanced-stage resectable melanoma. Currently, the mainstay of treatment of malignant melanoma is surgery followed by adjuvant systemic therapies. However, recent studies have shown a potential role for neoadjuvant therapy in the treatment of advanced-stage resectable melanoma. Mechanistically, neoadjuvant immunotherapy may yield a more robust response than adjuvant immunotherapy, as the primary tumor serves as an antigen in this setting rather than only micrometastatic disease after the index procedure. Additionally, targeted therapy has been shown to yield effective neoadjuvant cytoreduction, and oncolytic viruses may also increase the immunogenicity of primary tumors. Effective neoadjuvant therapy may serve to decrease tumor size and thus reduce the extent of required surgery and thus morbidity. It also allows for assessment of pathologic response, facilitating prognostication as well as tailoring future therapy. The current literature consistently supports that neoadjuvant therapy, even as little as one dose, is associated with improved outcomes and is well-tolerated. Some patients with a complete pathological response may even avoid surgery completely. These results challenge the current paradigm of a surgery-first approach and provide further evidence supporting neoadjuvant therapy in advanced-stage resectable melanoma. Further research into the optimal treatment schedule and dose timing is warranted, as is the continued investigation of novel therapies and combinations of therapies.